Big Pharma deals may lie ahead in 2013

01/8/2013 | Bloomberg · PharmaTimes (U.K.)

Pfizer and Merck are among the drugmakers with enough cash on hand to invest $10 billion or more in mergers and acquisitions this year. However, expiring patents on blockbuster drugs, more muscular biotechnology companies and stronger competition might impede Big Pharma's ability to conclude large deals, an Ernst & Young analysis found.

View Full Article in:

Bloomberg · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX